Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rhabdomyosarcoma, Child
Conditions
Rhabdomyosarcoma, Child
Trial Timeline
Dec 30, 2023 → Jul 31, 2026
NCT ID
NCT05457829About Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine is a phase 2 stage product being developed by Sun Pharmaceutical for Rhabdomyosarcoma, Child. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05457829. Target conditions include Rhabdomyosarcoma, Child.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05457829 | Phase 2 | Recruiting |
Competing Products
3 competing products in Rhabdomyosarcoma, Child
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin mesylate | Eisai | Phase 2 | 52 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 51 |
| Epirubicin Hydrochloride + Ifosfamide + Sorafenib Tosylate | Bayer | Phase 2 | 49 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85